Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 August 2025 | Story Precious Shamase
One Health research project
Pictured are Prof Steven Belmain, Dr Hayley Thompson, and Prof Lourens Swanepoel during their visit to South Africa to kick off a collaborative One Health research project aimed at addressing rodent-related health risks in townships – an initiative that unites local and international experts in the pursuit of safer, community-driven solutions.

A collaborative research project is underway in South African townships to combat the pervasive rodent problem and its impact on human health. Led by Prof Peter Taylor, Professor-in-Residence in the UFS Afromontane Research Unit and affiliated with the UFS Department of Zoology and Entomology, the initiative brings together experts from the UK's Natural Resources Institute (NRI), including Prof Steven Belmain and Dr Hayley Thompson, and South African institutions such as the UFS and the University of Venda.

This 'One Health' approach acknowledges the interconnectedness of human, animal, and environmental well-being. The team visited laboratory facilities at the UFS campuses in Bloemfontein and Qwaqwa, the latter being near Phuthaditjhaba township – a key research site alongside Lwamando in Limpopo.

The multidisciplinary project involves local farmers and university departments, integrating expertise in advanced techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, molecular virology and microbiology, genome sequencing, and parasitology. Social scientists, such as Dr Shingirayi Chamisa, a lecturer in the UFS Department of Industrial Psychology, are also involved to understand community perceptions and current rodent control methods, including the impact on mental health.

The research will investigate the health risks associated with rodent infestations, including food contamination with poison residues and fungal toxins, and the transmission of disease to humans and livestock through direct contact or parasites. Practical trials will evaluate methods to reduce food contamination.

Significantly, the project will explore novel and humane rodent control strategies, such as contraceptive baits, offering a safer alternative to rodenticides. Recent concerns about rodenticide-related deaths in townships have increased pressure for safer, ecological solutions.

This research holds significant promise for developing sustainable and effective solutions to mitigate the negative impact of rodent pests on the health and livelihoods of township residents. The international and local collaboration, guided by a holistic 'One Health' perspective, marks a crucial step towards addressing this challenging issue. Prof Taylor expressed his appreciation for the enthusiastic engagement of all collaborators, highlighting the potential for a truly transdisciplinary project to find meaningful and ecologically sound solutions to rodent-borne pathogens and food contamination in South African townships.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept